Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis

Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis

Here, we report a novel antibody drug conjugate (ADC) with the humanized anti-CD26 monoclonal antibody YS110 and triptolide (TR-1). YS110 has an inhibitory activity against the CD26-positive tumor growth via the immunological and direct pathway, such as intra-nuclear transportation of CD26 and YS110...

Full description

Bibliographic Details
Main Authors: Mutsumi Hayashi, Hiroko Madokoro, Koji Yamada, Hiroko Nishida, Chikao Morimoto, Michiie Sakamoto, Hiroshi Yanagawa, Taketo Yamada
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
antibody drug conjugate
targeted therapy
CD26
triptolide
RNA polymerase II
malignant mesothelioma
Online Access:https://www.mdpi.com/2072-6694/11/8/1138

Internet

https://www.mdpi.com/2072-6694/11/8/1138

Similar Items